BR9710030A - Processo de produção de adenovírus recombinantes processo de purificação de adenovírus recombinantes a partir de um meio biológico preparação viral purificada composição farmacêutica e utilização de iodixanol-5,5'-[(2-Hidroxipropil-1,3-Propanottl)-Bis[N,N'-Bis(2,3-Didroxipropil-2,4,6-Triodo-1,3-Benzenocarboxamida] - Google Patents
Processo de produção de adenovírus recombinantes processo de purificação de adenovírus recombinantes a partir de um meio biológico preparação viral purificada composição farmacêutica e utilização de iodixanol-5,5'-[(2-Hidroxipropil-1,3-Propanottl)-Bis[N,N'-Bis(2,3-Didroxipropil-2,4,6-Triodo-1,3-Benzenocarboxamida]Info
- Publication number
- BR9710030A BR9710030A BR9710030A BR9710030A BR9710030A BR 9710030 A BR9710030 A BR 9710030A BR 9710030 A BR9710030 A BR 9710030A BR 9710030 A BR9710030 A BR 9710030A BR 9710030 A BR9710030 A BR 9710030A
- Authority
- BR
- Brazil
- Prior art keywords
- bis
- recombinant adenoviruses
- propanottl
- didroxypropyl
- benzenocarboxamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/145—Ultrafiltration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J41/00—Anion exchange; Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
- B01J41/20—Anion exchangers for chromatographic processes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Water Supply & Treatment (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9608164A FR2750433B1 (fr) | 1996-07-01 | 1996-07-01 | Procede de production d'adenovirus recombinants |
US2666796P | 1996-09-25 | 1996-09-25 | |
PCT/FR1997/001107 WO1998000524A1 (fr) | 1996-07-01 | 1997-06-20 | Procede de production d'adenovirus recombinants |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9710030A true BR9710030A (pt) | 1999-08-10 |
Family
ID=26232805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9710030A BR9710030A (pt) | 1996-07-01 | 1997-06-20 | Processo de produção de adenovírus recombinantes processo de purificação de adenovírus recombinantes a partir de um meio biológico preparação viral purificada composição farmacêutica e utilização de iodixanol-5,5'-[(2-Hidroxipropil-1,3-Propanottl)-Bis[N,N'-Bis(2,3-Didroxipropil-2,4,6-Triodo-1,3-Benzenocarboxamida] |
Country Status (13)
Country | Link |
---|---|
US (3) | US6485958B2 (pt) |
EP (1) | EP0944717A1 (pt) |
JP (1) | JP2000514290A (pt) |
KR (1) | KR20050043996A (pt) |
AU (1) | AU3447097A (pt) |
BR (1) | BR9710030A (pt) |
CA (1) | CA2258158A1 (pt) |
CZ (1) | CZ438398A3 (pt) |
HU (1) | HU224558B1 (pt) |
IL (1) | IL127692A0 (pt) |
NO (1) | NO986202L (pt) |
SK (1) | SK181098A3 (pt) |
WO (1) | WO1998000524A1 (pt) |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0847442A1 (en) * | 1995-08-30 | 1998-06-17 | Genzyme Corporation | Chromatographic purification of adenovirus and aav |
IL127692A0 (en) * | 1996-07-01 | 1999-10-28 | Rhone Poulenc Rorer Sa | Method for producing recombinant adenovirus |
US7732129B1 (en) * | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
KR100503701B1 (ko) | 1996-11-20 | 2005-07-26 | 인트로겐 테라페티스, 인코퍼레이티드 | 아데노바이러스 벡터를 생산하고 정제하는 개선된 방법 |
US6544769B1 (en) * | 1996-12-13 | 2003-04-08 | Schering Corporation | Compostions comprising viruses and methods for concentrating virus preparations |
ATE477320T1 (de) | 1996-12-13 | 2010-08-15 | Schering Corp | Methoden zur virus-reinigung |
US20080261289A1 (en) * | 1996-12-13 | 2008-10-23 | Schering-Plough Corporation | Compositions comprising viruses and methods for concentrating virus preparations |
US6146891A (en) * | 1997-01-31 | 2000-11-14 | Schering Corporation | Methods for cultivating cells and propagating viruses |
US6995006B2 (en) * | 1997-09-05 | 2006-02-07 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
AU756889B2 (en) | 1998-04-22 | 2003-01-23 | Genvec, Inc. | Efficient purification of adenovirus |
AU770672B2 (en) * | 1998-05-27 | 2004-02-26 | University Of Florida | Method of preparing recombinant adeno-associated virus compositions by using an iodixananol gradient |
EP1080218A1 (en) | 1998-05-27 | 2001-03-07 | University of Florida | Method of preparing recombinant adeno-associated virus compositions by using an iodixanol gradient |
US6689600B1 (en) | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
CZ20012428A3 (cs) * | 1998-12-31 | 2001-11-14 | Aventis Pharma S. A. | Způsob separace virových částic |
FR2788064B1 (fr) * | 1998-12-31 | 2003-01-31 | Aventis Pharma Sa | Methode de separation de particules virales |
DE60029195T2 (de) | 1999-02-22 | 2007-06-28 | Transgene S.A. | Verfahren zur Gewinnung von purifizierter Virenzusammensetzung |
US6783939B2 (en) * | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
WO2003014367A1 (en) * | 2001-08-08 | 2003-02-20 | The Trustees Of The University Of Pennsylvania | Method for purification of viral vectors having proteins which bind sialic acid |
EP1432791B2 (en) * | 2001-09-06 | 2013-10-23 | Alphavax, Inc. | Alphavirus replicon vector systems |
EP1453536A4 (en) | 2001-12-12 | 2009-08-26 | Mayne Pharma Int Pty Ltd | COMPOSITION FOR PRESERVING VIRUSES |
US20030232018A1 (en) * | 2002-01-18 | 2003-12-18 | Berlex Biosciences | Stabilized formulations of adenovirus |
US20030224354A1 (en) * | 2002-05-30 | 2003-12-04 | Introgen Therapeutics Inc. | Quantifying viral particles with intrinsic fluorescence |
EP1371723A1 (en) * | 2002-06-12 | 2003-12-17 | Procorde GmbH | Process for preparing an adenovirus-containing preparation |
AU2003268210A1 (en) * | 2002-08-28 | 2004-03-19 | Introgen Therapeutics Inc. | Chromatographic methods for adenovirus purification |
AU2003297041B2 (en) * | 2002-12-13 | 2009-02-26 | Alphavax, Inc. | Alphavirus particles and methods for preparation |
WO2004055166A2 (en) * | 2002-12-13 | 2004-07-01 | Alphavax, Inc. | Multi-antigenic alphavirus replicon particles and methods |
CN1791678A (zh) * | 2003-03-20 | 2006-06-21 | 阿尔法瓦克斯公司 | 改进的甲病毒复制子和辅助构建体 |
US20040229335A1 (en) | 2003-05-15 | 2004-11-18 | Introgen Therapeutics, Inc. | Methods and compositions for the production of adenoviral vectors |
CN1816619A (zh) * | 2003-06-18 | 2006-08-09 | 昂尼克斯药物公司 | 纯化病毒的方法 |
WO2005007689A1 (en) * | 2003-07-11 | 2005-01-27 | Alphavax, Inc. | Alphavirus-based cytomegalovirus vaccines |
AU2004263274B2 (en) | 2003-07-21 | 2009-11-05 | Transgene S.A. | Novel multifunctional cytokines |
AU2005214090B2 (en) * | 2004-02-23 | 2008-09-11 | Crucell Holland B.V. | Virus purification methods |
AU2005245956B2 (en) * | 2004-05-18 | 2011-05-19 | Alphavax, Inc. | TC-83-derived alphavirus vectors, particles and methods |
CA2586107A1 (en) * | 2004-11-03 | 2006-05-18 | Introgen Therapeutics Inc. | A novel method for the production and purification of adenoviral vectors |
US8900804B2 (en) * | 2004-11-22 | 2014-12-02 | Cedars-Sinai Medical Center | Methods and solutions for tissue preservation |
NZ561681A (en) | 2005-03-21 | 2011-01-28 | Virobay Inc | Alpha ketoamide compounds as cysteine protease inhibitors |
CN101155915B (zh) * | 2005-04-11 | 2013-12-04 | 克鲁塞尔荷兰公司 | 利用超滤进行病毒纯化 |
US8465732B2 (en) | 2007-01-19 | 2013-06-18 | Cornell Research Foundation, Inc. | Endothelial cells expressing adenovirus E4ORF1 and methods of use thereof |
CN101617052A (zh) | 2007-01-30 | 2009-12-30 | 特兰斯吉恩股份有限公司 | 用于免疫的乳头瘤病毒e2多肽 |
PL2947149T3 (pl) * | 2007-06-21 | 2018-09-28 | Alphavax, Inc. | Kasety bez promotora do ekspresji alfawirusowych białek strukturalnych |
ES2532015T3 (es) * | 2008-11-03 | 2015-03-23 | Crucell Holland B.V. | Método para la producción de vectores adenovíricos |
SG178254A1 (en) | 2009-08-07 | 2012-03-29 | Transgene Sa | Composition for treating hbv infection |
AU2010305765B2 (en) | 2009-10-15 | 2015-07-02 | Crucell Holland B.V. | Method for the purification of adenovirus particles |
CN102575233B (zh) | 2009-10-15 | 2014-07-16 | 克鲁塞尔荷兰公司 | 从高细胞密度培养物纯化腺病毒的方法 |
WO2011098592A1 (en) | 2010-02-15 | 2011-08-18 | Crucell Holland B.V. | Method for the production of ad26 adenoviral vectors |
JP2013523175A (ja) * | 2010-04-14 | 2013-06-17 | イーエムディー・ミリポア・コーポレーション | 高力価、高純度のウイルスストックの作製方法及びその使用方法 |
CA2819552C (en) | 2010-12-09 | 2023-09-26 | Institut Pasteur | Mgmt-based method for obtaining high yield of recombinant protein expression |
TWI575070B (zh) | 2011-07-12 | 2017-03-21 | 傳斯堅公司 | Hbv聚合酶突變體 |
TW201318637A (zh) | 2011-09-29 | 2013-05-16 | Transgene Sa | 免疫療法組成物及用於治療c型肝炎病毒感染之療程(一) |
WO2013045668A2 (en) | 2011-09-29 | 2013-04-04 | Transgene Sa | Immunotherapy composition and regimen for treating hepatitis c virus infection |
CN104379733B (zh) | 2012-03-12 | 2016-01-20 | 克鲁塞尔荷兰公司 | 具改变末端的重组腺病毒群 |
US9125870B2 (en) | 2012-03-22 | 2015-09-08 | Crucell Holland B.V. | Vaccine against RSV |
MY169352A (en) | 2012-03-22 | 2019-03-25 | Janssen Vaccines & Prevention Bv | Vaccine against rsv |
CA2875683A1 (en) | 2012-06-05 | 2013-12-12 | The Australian National University | Vaccination with interleukin-4 antagonists |
US9657076B2 (en) | 2012-10-23 | 2017-05-23 | Emory University | GM-CSF and IL-4 conjugates, compositions, and methods related thereto |
CA2902650A1 (en) * | 2013-02-28 | 2014-09-04 | Psioxus Therapeutics Limited | A process for the production of adenovirus |
KR102089121B1 (ko) | 2013-03-14 | 2020-03-13 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 종양살상형 아데노바이러스 조성물 |
MX361774B (es) | 2013-04-25 | 2018-12-17 | Janssen Vaccines & Prevention Bv | Polipéptidos f de prefusión del virus sincicial respiratorio (rsv) solubles y estabilizados. |
PE20160045A1 (es) | 2013-06-17 | 2016-02-18 | Crucell Holland Bv | Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados |
GB201415579D0 (en) * | 2014-09-03 | 2014-10-15 | Psioxus Therapeutics Ltd | A process |
AU2015279552B2 (en) * | 2014-06-27 | 2021-01-21 | Angiocrine Bioscience, Inc. | Neural cells expressing adenovirus E4ORF1, and methods of making and using the same |
WO2016030489A2 (en) * | 2014-08-27 | 2016-03-03 | Psioxus Therapeutics Limited | A process for the production of adenovirus |
SG11201704919SA (en) | 2015-01-13 | 2017-07-28 | Alfa Wassermann Inc | Methods of purifying adeno-associated virus (aav) and/or recombinant adeno-associated virus (raav) |
WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
US10570417B2 (en) | 2015-04-14 | 2020-02-25 | Janssen Vaccines & Prevention B.V. | Recombinant adenovirus expressing two transgenes with a bidirectional promoter |
JP6840718B2 (ja) | 2015-07-07 | 2021-03-10 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | 安定化された可溶性融合前rsv fポリペプチド |
WO2017005844A1 (en) | 2015-07-07 | 2017-01-12 | Janssen Vaccines & Prevention B.V. | Vaccine against rsv |
EP3390428B1 (en) * | 2016-02-23 | 2019-09-25 | Salk Institute for Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
CN117384961A (zh) | 2016-02-23 | 2024-01-12 | 萨克生物研究学院 | 对病毒动力学影响最小的治疗性腺病毒中的外源基因表达 |
BR112018070323A2 (pt) | 2016-04-05 | 2019-01-29 | Janssen Vaccines & Prevention Bv | vacina contra rsv |
AU2017248021B2 (en) | 2016-04-05 | 2021-08-12 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F proteins |
US20190134190A1 (en) | 2016-05-04 | 2019-05-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
RU2758238C2 (ru) | 2016-05-12 | 2021-10-26 | Янссен Вэксинс Энд Превеншн Б.В. | Эффективный и сбалансированный двунаправленный промотор |
WO2017207480A1 (en) | 2016-05-30 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
US11001858B2 (en) | 2016-06-20 | 2021-05-11 | Janssen Vaccines & Prevention B.V. | Potent and balanced bidirectional promoter |
WO2018011196A1 (en) | 2016-07-14 | 2018-01-18 | Janssen Vaccines & Prevention B.V. | Hpv vaccines |
EP3522920A2 (en) | 2016-10-10 | 2019-08-14 | Transgene SA | Immunotherapeutic product and mdsc modulator combination therapy |
CN110418650A (zh) | 2016-11-16 | 2019-11-05 | 免疫治疗有限公司 | 用于治疗过敏的核酸 |
CN110062630A (zh) | 2016-12-12 | 2019-07-26 | 萨克生物研究学院 | 肿瘤靶向合成腺病毒及其用途 |
KR102111244B1 (ko) | 2017-02-09 | 2020-05-15 | 얀센 백신스 앤드 프리벤션 비.브이. | 이종 유전자의 발현을 위한 강력한 짧은 프로모터 |
US11203629B2 (en) | 2017-04-22 | 2021-12-21 | Immunomic Therapeutics, Inc. | LAMP constructs |
AU2018263923A1 (en) | 2017-05-02 | 2019-10-31 | Immunomic Therapeutics, Inc. | LAMP (lysosomal associated membrane protein) constructs comprising cancer antigens |
EP3624844A1 (en) | 2017-05-17 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
EP3681533A1 (en) | 2017-09-15 | 2020-07-22 | Janssen Vaccines & Prevention B.V. | Method for the safe induction of immunity against rsv |
WO2019222281A1 (en) | 2018-05-15 | 2019-11-21 | Immunomic Therapeutics, Inc | Improved lamp constructs comprising allergens |
TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
CN113710810A (zh) | 2019-02-21 | 2021-11-26 | 安利舒免疫溶瘤技术公司 | 溶瘤腺病毒载体和使用方法 |
CA3153850A1 (en) | 2019-10-18 | 2021-04-22 | Teri Heiland | Improved lamp constructs comprising cancer antigens |
AU2020385683A1 (en) | 2019-11-18 | 2022-06-30 | Janssen Biotech, Inc. | Vaccines based on mutant CALR and JAK2 and their uses |
TW202144388A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在卵巢癌中表現之新抗原及其用途 |
TW202144389A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在多發性骨髓瘤中表現之新抗原及其用途 |
JP2023521194A (ja) | 2020-04-13 | 2023-05-23 | ヤンセン バイオテツク,インコーポレーテツド | Psma及びsteap1ワクチン並びにそれらの使用 |
EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
US20230024133A1 (en) | 2020-07-06 | 2023-01-26 | Janssen Biotech, Inc. | Prostate Neoantigens And Their Uses |
US20230035403A1 (en) | 2020-07-06 | 2023-02-02 | Janssen Biotech, Inc. | Method For Determining Responsiveness To Prostate Cancer Treatment |
WO2023201201A1 (en) | 2022-04-10 | 2023-10-19 | Immunomic Therapeutics, Inc. | Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5173418A (en) * | 1985-05-10 | 1992-12-22 | Benzon Pharma, A/S | Production in Escherichia coli of extracellular Serratia spp. hydrolases |
FR2705686B1 (fr) * | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
CA2181066A1 (en) * | 1994-01-12 | 1995-07-20 | Hitoshi Kotani | Purification of retroviral vectors |
FR2716893B1 (fr) * | 1994-03-03 | 1996-04-12 | Rhone Poulenc Rorer Sa | Virus recombinants, leur préparation et leur utilisation thérapeutique. |
AU2127395A (en) | 1994-03-22 | 1995-10-09 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Highly efficient production and isolation of viral particles |
US5837520A (en) * | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
IL127692A0 (en) * | 1996-07-01 | 1999-10-28 | Rhone Poulenc Rorer Sa | Method for producing recombinant adenovirus |
KR100503701B1 (ko) | 1996-11-20 | 2005-07-26 | 인트로겐 테라페티스, 인코퍼레이티드 | 아데노바이러스 벡터를 생산하고 정제하는 개선된 방법 |
US6261823B1 (en) * | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
CZ20012428A3 (cs) * | 1998-12-31 | 2001-11-14 | Aventis Pharma S. A. | Způsob separace virových částic |
-
1997
- 1997-06-20 IL IL12769297A patent/IL127692A0/xx unknown
- 1997-06-20 BR BR9710030A patent/BR9710030A/pt not_active Application Discontinuation
- 1997-06-20 KR KR1020057007148A patent/KR20050043996A/ko active IP Right Grant
- 1997-06-20 CA CA002258158A patent/CA2258158A1/fr not_active Abandoned
- 1997-06-20 CZ CZ984383A patent/CZ438398A3/cs unknown
- 1997-06-20 HU HU0001271A patent/HU224558B1/hu not_active IP Right Cessation
- 1997-06-20 SK SK1810-98A patent/SK181098A3/sk unknown
- 1997-06-20 US US09/202,545 patent/US6485958B2/en not_active Expired - Fee Related
- 1997-06-20 JP JP10503872A patent/JP2000514290A/ja not_active Ceased
- 1997-06-20 AU AU34470/97A patent/AU3447097A/en not_active Abandoned
- 1997-06-20 EP EP97930560A patent/EP0944717A1/fr not_active Ceased
- 1997-06-20 WO PCT/FR1997/001107 patent/WO1998000524A1/fr not_active Application Discontinuation
-
1998
- 1998-12-30 NO NO986202A patent/NO986202L/no not_active Application Discontinuation
-
2002
- 2002-10-10 US US10/267,865 patent/US6905862B2/en not_active Expired - Fee Related
-
2005
- 2005-03-23 US US11/086,678 patent/US20050287657A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US6485958B2 (en) | 2002-11-26 |
NO986202D0 (no) | 1998-12-30 |
US20020028497A1 (en) | 2002-03-07 |
HUP0001271A3 (en) | 2002-01-28 |
KR20050043996A (ko) | 2005-05-11 |
US20050287657A1 (en) | 2005-12-29 |
AU3447097A (en) | 1998-01-21 |
CA2258158A1 (fr) | 1998-01-08 |
EP0944717A1 (fr) | 1999-09-29 |
SK181098A3 (en) | 1999-07-12 |
US20030143730A1 (en) | 2003-07-31 |
JP2000514290A (ja) | 2000-10-31 |
US6905862B2 (en) | 2005-06-14 |
HUP0001271A1 (hu) | 2000-08-28 |
IL127692A0 (en) | 1999-10-28 |
CZ438398A3 (cs) | 1999-03-17 |
HU224558B1 (hu) | 2005-10-28 |
WO1998000524A1 (fr) | 1998-01-08 |
NO986202L (no) | 1999-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9710030A (pt) | Processo de produção de adenovírus recombinantes processo de purificação de adenovírus recombinantes a partir de um meio biológico preparação viral purificada composição farmacêutica e utilização de iodixanol-5,5'-[(2-Hidroxipropil-1,3-Propanottl)-Bis[N,N'-Bis(2,3-Didroxipropil-2,4,6-Triodo-1,3-Benzenocarboxamida] | |
LU91314I2 (fr) | "Combinaison de particules viroides de papillomavirus humain de type 6, 11, 16 et 18 (GARDASIL -GilGARD )" | |
DE69721840D1 (en) | Zuckerrohr bacilliformviruspromotor | |
AU7007491A (en) | Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses | |
BR9205163A (pt) | Processo para a preparacao de protease alcalina altamente purificada a partir de um caldo de fermentacao,composicao e protease alcalina purificada | |
DK0386734T3 (da) | Immunogene regioner på E-7-proteinet af humant papillomavirus type 16 | |
BR9807618A (pt) | Análogo de fator xdelta, dna recombinante codificante para um análogo de fator xdelta, células transformadas, preparação, uso da mesma, e, processos para produzir uma preparação contendo análogo de fator xdelta recombinante purificado e análogo de fator xa. | |
GB2287024B (en) | Preparation and purification of L-5-(2-hydroxypropylamino)-2,4,6-triiodoisophthalic acid bis-(1,3-dihydroxypropylamide) contrast agent | |
WO1996029413A3 (en) | Dna encoding human papilloma virus type 18 | |
PT84041B (pt) | Processo para a preparacao do cloridrato de s-(-)-1-propil-2',6'-pipecoloxilidido monohidratado opticamente puro e de composicoes farmaceuticas que o contem | |
BR9708227A (pt) | Processo de purificação de dna duplo filamento de pureza farmacêutica preparação de dna plasmídico recombinante e composição farmacêutica | |
CA2200582A1 (en) | Dna encoding human papillomavirus type 6a | |
FR2608159B1 (fr) | Nouveaux derives de l'acide furannuronique, leur preparation et leur utilisation comme medicaments | |
PT87004A (pt) | Process for the preparation of compositions for the treatment of viral infections and composites 3'-azide-2',3'-didesoxy-in osine and 3'-fluoro-2',3'-didesoxyguanosine | |
BR9501546A (pt) | Processo para a preparação de 2,2-difluorceteno silil O,S-acetais processo para preparar tioésteres de ácido alfa alfa-diflúor-beta-sililóxi-1,3-dioxolano-4-propanóico e 2,2-difluorceteno silil O,S-acetato obtido | |
IL120483A (en) | Process for the preparation of (S)-N-N'-bis¬2-hydroxy-1-hydroxymethyl)ethyl¾-5-(2-acetoxy-propionylamino)-2,4,6-triiodo-isophthalamide | |
FR2727111B1 (fr) | Nouveaux analogues soufres d'aminoacides, leur procede de preparation et leurs applications comme medicaments | |
KR960701075A (ko) | 신규 2'-메틸리덴 뉴클레오티드 화합물, 그의 제조 방법 및 그의 약학적 용도[novel 2'-methylidenenucleotide compound, process for producing the same, and pharmaceutical use thereof] | |
FR2601021B2 (fr) | Fraction immunogene active a l'egard des bilharzioses, sa preparation, compositions immunisantes la contenant | |
IT1198230B (it) | Procedimento per individuare la velocita' e i paramenti operativi ottimali di roccatura per ogni tipo di filato | |
IT1189070B (it) | Processo per la preparazione della l(-)-carnitina cloruro a partire da esteri 3,4-epossibutirrici | |
YU48589A (en) | Process for improved preparation of4,4'-dinitro-stilbene-2,2'-disulphonic acid and it's salts | |
FR2603303B1 (fr) | Procede de preparation de la carnitine par hydrolyse du carnitinamide, l'enzyme nouvelle utilisee dans ce procede et sa preparation | |
BR9909576A (pt) | Genes de receptor de transferrina de moraxella | |
IT8622780A0 (it) | "2-cloro-12-(-3-dimetilammino-2-metilpropil)-12h-dibenzo-/d,g//1,3,6/d iossazocine otticamente attive eprocedimento per la loro preparazione. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TC | Change of name | ||
B25A | Requested transfer of rights approved |
Owner name: GENCELL S.A. (FR) Free format text: TRANSFERIDO DE: AVENTIS PHARMA S.A. |
|
B25F | Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement |
Owner name: GENCELL S.A. (FR) Free format text: A FIM DE ATENDER AO PEDIDO DE ALTERACAO DE NOME CONTIDO NA PETICAO NO 030277/RJ, DE 31/05/04, APRESENTE O DEVIDO DOCUMENTO DE ALTERACAO DE RAZAO SOCIAL. |
|
B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: GENCELL S.A. (FR) Free format text: REFERENTE A RPI 1856 COD. (25.6) DE 01/08/2006, POR TER SIDO INDEVIDO. |
|
B25D | Requested change of name of applicant approved |
Owner name: GENCELL SAS (FR) Free format text: ALTERADO DE: GENCELL S.A. |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: O DEPOSITANTE DEIXOU DE APRESENTAR MANIFESTACAO SOBRE O PARECER NEGATIVO, ASSIM, DE ACORDO COM O ART. 36 DA LPI (LEI 9279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR. |
|
B25D | Requested change of name of applicant approved |
Owner name: CENTELION S.A.S. (FR) Free format text: ALTERADO DE: GENCELL SAS |